Efficacy of Danlou Tablet in Patients with Non-ST Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Results from a Multicentre, Placebo-Controlled, Randomized Trial
Joint Authors
Guo, Liheng
Liu, Shaonan
Yang, Haiyu
Wu, Yang
Chen, Keji
Cong, Hongliang
Wang, Lei
Zhao, Xujie
Mao, Shuai
Du, Tinghai
Zhao, Fuhai
Wu, Keng
Yang, Phillip C.
Zhang, Minzhou
Guo, Xinfeng
Source
Evidence-Based Complementary and Alternative Medicine
Issue
Vol. 2016, Issue 2016 (31 Dec. 2016), pp.1-10, 10 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2016-11-08
Country of Publication
Egypt
No. of Pages
10
Main Subjects
Abstract EN
This study seeks to investigate potential cardioprotection of Danlou Tablets in patients undergoing PCI with non-ST elevation acute coronary syndrome (NSTE-ACS).
219 patients with NSTE-ACS were randomised to Danlou Tablet pretreatment (n=109) or placebo (n=110).
No patients received statins prior to PCI and all patients were given atorvastatin (10 mg/day) after procedure.
The main endpoint was the composite incidence of major adverse cardiac events (MACEs) within 30 days after PCI.
The proportion of patients with elevated levels of cTn I>5 × 99% of upper reference limit was significantly lower in the Danlou Tablet group at 8 h (22.0% versus 34.5%, p=0.04) and 24 h (23.9% versus 38.2%, p=0.02) after PCI.
The 30-day MACEs occurred in 22.0% of the Danlou Tablet group and 33.6% in the placebo group (p=0.06).
The incidence of MACE at 90-day follow-up was significantly decreased in the Danlou Tablet group compared to the placebo group (23.9% versus 37.3%, p=0.03).
The difference between the groups at 90 days was the incidence of nonfatal myocardial infarction (22% versus 34.5%, p=0.04).
These findings might support that treatment with Danlou Tablet could reduce the incidence of periprocedural myocardial infarction in patients with ACS undergoing PCI.
American Psychological Association (APA)
Wang, Lei& Zhao, Xujie& Mao, Shuai& Liu, Shaonan& Guo, Xinfeng& Guo, Liheng…[et al.]. 2016. Efficacy of Danlou Tablet in Patients with Non-ST Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Results from a Multicentre, Placebo-Controlled, Randomized Trial. Evidence-Based Complementary and Alternative Medicine،Vol. 2016, no. 2016, pp.1-10.
https://search.emarefa.net/detail/BIM-1104395
Modern Language Association (MLA)
Wang, Lei…[et al.]. Efficacy of Danlou Tablet in Patients with Non-ST Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Results from a Multicentre, Placebo-Controlled, Randomized Trial. Evidence-Based Complementary and Alternative Medicine No. 2016 (2016), pp.1-10.
https://search.emarefa.net/detail/BIM-1104395
American Medical Association (AMA)
Wang, Lei& Zhao, Xujie& Mao, Shuai& Liu, Shaonan& Guo, Xinfeng& Guo, Liheng…[et al.]. Efficacy of Danlou Tablet in Patients with Non-ST Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Results from a Multicentre, Placebo-Controlled, Randomized Trial. Evidence-Based Complementary and Alternative Medicine. 2016. Vol. 2016, no. 2016, pp.1-10.
https://search.emarefa.net/detail/BIM-1104395
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1104395